We are studying whether Senicapoc can help slow the progression of lung disease in patients with progressive fibrotic ILD. This trial compares its effects to a placebo alongside standard care.
Health conditions and diseases that the clinical trial is designed to study and treat.
Interstitial Pulmonary Fibrosis (IPF) is a serious lung disease that causes progressive scarring of lung tissue, making it difficult to breathe. This condition can lead to severe respiratory issues and is often associated with a decline in lung function over time.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
